Gómez-Belda A, Rodilla E, González C, Costa J A, Serra B, Pascual J M
Unidades de Hipertensión y Riesgo Vascular, Servicio de Medicina Interna, Hospital de Sagunto, Valencia. España.
Rev Clin Esp. 2006 Oct;206(9):417-21. doi: 10.1157/13093465.
The last modifications of the National Cholesterol Education Program (NCEP) indicate some lower therapeutic targets of low density protein cholesterol (LDL-c) in patients with very high vascular risk. Our study aims to establish the degree of compliance of the therapeutic targets defined by these modifications.
Descriptive and cross sectional study of patients from a cardiovascular clinic. Low-density lipoprotein cholesterol (LDL-c) was calculated and targets were established according the new update of NCEP-ATP III.
836 patients, 625 (75%) with HR and 211(25%) with VHR were studied 45% of HR and 67% of VHR were receiving treatment with statins (p < 0.001) but only 38% of HR and 15% of VHR achieved target LDL-c levels. The percentage of patients who could achieve LDL-goals using the maximum approved dose of the statins plus other lipid lowering drug was calculated: The 31% of HR and 51% of VHR were unable to achieve the LDL-c targets.
Only 15% of very high risk patients achieve target levels of LDL-c according to the new NCEP-ATP III recommendations. Even using maximum dose of statins in combination with other lipid lowering drugs, less than half of the patients will be able to achieve LDL-c goal (< 70 mg/dl).
美国国家胆固醇教育计划(NCEP)的最新修订指出,对于血管风险极高的患者,低密度脂蛋白胆固醇(LDL-c)的治疗目标有所降低。我们的研究旨在确定这些修订所定义的治疗目标的依从程度。
对一家心血管诊所的患者进行描述性横断面研究。计算低密度脂蛋白胆固醇(LDL-c),并根据NCEP-ATP III的新更新确定目标。
研究了836例患者,其中625例(75%)为高危(HR)患者,211例(25%)为极高危(VHR)患者。45%的HR患者和67%的VHR患者接受他汀类药物治疗(p < 0.001),但只有38%的HR患者和15%的VHR患者达到了LDL-c目标水平。计算了使用他汀类药物最大批准剂量加其他降脂药物可达到LDL目标的患者百分比:31%的HR患者和51%的VHR患者无法达到LDL-c目标。
根据新的NCEP-ATP III建议,只有15%的极高危患者达到了LDL-c目标水平。即使使用他汀类药物最大剂量联合其他降脂药物,也不到一半的患者能够达到LDL-c目标(< 70 mg/dl)。